Table 1.

Median (IQR) and mean (SD) Ki-67 level at baseline and surgery, change (Δ) and percentage change by molecular subtype

	n	Median Ki-67 (IQR)	Mean (SD)
Overall
Baseline biopsy	269	26 (15, 43)	31.3 (21.3)
End point surgery		28 (17, 42)	33.4 (22.4)
Change		0 (−2, 6)	2.2 (9.2)
%change		0 (−6.7, 28.6)	13.58 (45.14)
Luminal-A
Baseline biopsy	46	10 (7, 11)	8.8 (2.8)
End point surgery		10 (8, 14)	10.8 (5.2)
Change		0 (0, 4)	1.9 (4.8)
%change		0 (0, 50)	29.55 (70.02)
Luminal-B
Baseline biopsy	85	20 (17, 29)	24.5 (11.4)
End point surgery		22 (18, 30)	25 (12.8)
Change		0 (−5, 4)	0.5 (10.2)
%change		0 (−16.67, 22.22)	6.79 (45.5)
Luminal-B
HER2-positive
Baseline biopsy	24	28 (21.5, 35)	27.5 (9.9)
End point surgery		28 (24, 35)	29.8 (10)
Change		0 (−1.5, 7.5)	2.3 (7)
%change		0 (−5.26, 32.78)	15.6 (33.3)
HER2-positive
Baseline biopsy	36	30 (24.5, 45)	33.3 (13.8)
End point surgery		35.5 (29.5, 45)	38.4 (15.8)
Change		4 (0, 9)	5.1 (9.4)
%change		15.2 (0, 31.7)	18.37 (27.88)
Triple-negative
Baseline biopsy	78	50 (30, 75)	52 (22.9)
End point surgery		53.5 (39, 80)	54.9 (23.3)
Change		0 (−2, 10)	2.8 (10.4)
%change		0 (−3.8, 23.1)	8.74 (32.31)